Related by context. All words. (Click for frequent words.) 81 Phase 2a trial 80 Phase 2b study 80 Phase IIa 80 Phase 2a clinical 79 Phase IIa clinical 79 phase IIa clinical 79 Phase 2b trial 79 phase IIa 78 Phase 2a 78 Phase IIb trial 78 Phase Ib 77 Phase IIb 77 Phase IIb trials 77 phase IIb clinical 77 Phase IIb clinical 76 phase IIb 76 Phase 1b trial 75 Phase Ib study 75 Phase 2b clinical 75 Phase Ib clinical 75 Phase III clinical 75 phase IIb trial 74 Phase IIIb clinical 74 Phase III trials 74 phase IIb study 74 Phase 1b 74 pivotal Phase III 74 phase 2a 74 Phase III clinical trials 74 Phase 1b clinical 74 Phase 2b 73 Phase III 73 phase Ib 72 Phase IIa trials 72 Phase 1a clinical 72 Phase Ia 71 dose escalation Phase 71 Phase 2b clinical trials 71 dose escalation trial 71 Phase 1a 71 cannabinor 71 randomized Phase IIb 71 multicenter Phase II 71 confirmatory Phase III 71 Phase III pivotal 70 clinical trial 70 dirucotide 70 pharmacokinetic PK study 70 Phase #b/#a 70 phase Ib clinical 70 Phase Ib clinical trials 70 INCB# [001] 70 Phase IIb clinical trials 70 registrational trial 70 registrational 70 Phase Ib II 70 PRX # 70 dose escalation clinical 70 RSD# oral 69 TACI Ig 69 dose escalation study 69 phase IIIb 69 Corlux 69 multiple ascending dose 69 confirmatory Phase 3 69 clinical pharmacology studies 69 CR# vcMMAE 69 GALNS 69 placebo controlled Phase 69 dose cohort 69 randomized controlled Phase 68 Phase IIIb 68 oral ridaforolimus 68 Phase IIIb study 68 APEX PD 68 IMA# 68 ruxolitinib 68 ADVANCE PD 68 budesonide foam 68 Phenoptin 68 elacytarabine 68 multicenter Phase 68 FOLOTYN ® 68 ADAGIO study 68 NGX# 68 forodesine 68 Ocrelizumab 68 Phase IIa clinical trials 68 SUCCEED trial 68 Phase #b/#a trial 68 CEQ# 68 rALLy clinical trial 67 IIa trial 67 IIa clinical trial 67 pivotal Phase 67 elotuzumab 67 placebo controlled clinical 67 Zenvia Phase III 67 Archexin 67 Phase #/#a 67 Phase 2a clinical trials 67 clinical trials 67 pharmacokinetic studies 67 brivaracetam 67 Mipomersen 67 ATL# [001] 67 IND submission 67 Phase III placebo controlled 67 Traficet EN 67 alvespimycin 67 Phase II 67 initiate Phase IIb 67 alemtuzumab Campath 67 JAK inhibitor 67 Dacogen injection 67 pharmacokinetics PK 67 PEG PAL 67 Plicera 67 investigational compound 67 BLA submission 67 axitinib 66 Phase IIB 66 TBC# 66 oral prodrug 66 nonclinical studies 66 lomitapide 66 Amrubicin 66 diabetic neuropathic pain 66 fosbretabulin 66 Phase Ib IIa 66 midstage trials 66 GLP toxicology studies 66 dose cohorts 66 Phase 1b clinical trials 66 GAMMAGARD 66 randomized Phase III 66 mertansine 66 Phase III randomized controlled 66 CRLX# 66 ganetespib 66 alvimopan 66 PEG SN# 66 pivotal bioequivalence 66 Alzhemed TM 66 relapsed refractory multiple myeloma 66 KRN# 66 vidofludimus 66 MAGE A3 ASCI 66 histone deacetylase HDAC inhibitor 66 Fx #A 66 dyskinesia PD LID 66 huC# DM4 66 Phase #/#a trial 66 PSN# [002] 66 multicenter randomized Phase 66 bicifadine 66 initiate Phase 2b 66 AEG# 66 multicenter randomized placebo controlled 66 randomized Phase 66 dosing cohorts 66 Sym# 66 Aryplase 66 omacetaxine mepesuccinate 66 Triolex 66 ongoing Phase 1b 66 Pivotal Phase III 66 AZILECT ® 66 NP2 Enkephalin 66 glufosfamide 66 PXD# 66 Phase III Clinical Trial 66 PDE4 inhibitor 66 pharmacokinetic PK 66 tanespimycin 65 COMFORT II 65 oral rivaroxaban 65 viral kinetic 65 rALLy trial 65 randomized multicenter 65 preclinical efficacy 65 PD LID 65 single ascending dose 65 Augment Injectable 65 Proxinium TM 65 Cloretazine ® 65 MAA submission 65 lorvotuzumab mertansine 65 SNT MC# 65 BRIM3 65 HCV RESPOND 2 65 investigational humanized monoclonal antibody 65 PFO migraine 65 Cannabinor 65 riociguat 65 Azedra 65 II Clinical Trial 65 Ozarelix 65 Elocalcitol 65 Phase III Clinical Trials 65 teduglutide 65 preclinical studies 65 Phase IIb Trial 65 Personalized Immunotherapy 65 pharmacokinetic 65 RhuDex ® 65 GSK# [002] 65 bosutinib 65 PS# [001] 65 OvaRex R 65 virus HCV protease inhibitor 65 ABSORB trial 65 ELACYT 65 BCX# 65 ADX# 65 rNAPc2 65 teriflunomide 65 Fodosine 65 Safinamide 65 ENDEAVOR IV 65 VNP#M 65 Phase #b/#a clinical 65 BAY #-# 65 Annamycin 65 PANVAC VF 65 blinded randomized placebo controlled 65 ofatumumab HuMax CD# 65 PREOS 65 tezampanel 65 OvaRex ® MAb 65 metastatic hormone refractory 65 PNP inhibitor 65 ANCHOR trial 65 Elagolix 64 Diamyd ® 64 IL# PE#QQR 64 HGS ETR1 64 elagolix 64 Phase 2b Clinical Trial 64 HCV SPRINT 64 BRIM2 64 Phase IIb III 64 INCB# [002] 64 MEND CABG 64 Factor VIIa 64 Capesaris 64 GEM OS1 64 dosing cohort 64 BLA filing 64 CoFactor 64 enzastaurin 64 lintuzumab 64 AIR CF1 64 AQ4N 64 CRx 64 TMC# C# 64 ocrelizumab 64 TELINTRA 64 lintuzumab SGN 64 CA4P 64 CUSTOM III 64 investigational pan BCR 64 Zenvia ™ 64 placebo controlled 64 Memryte 64 eltrombopag 64 subcutaneously administered 64 HGS# 64 safinamide 64 midstage clinical 64 pertuzumab 64 placebo controlled Phase III 64 multicenter Phase III 64 Gabapentin GR 64 deforolimus 64 EOquin 64 double blinded placebo 64 REVIVE Diabetes 64 IMC A# 64 Tarvacin TM 64 PROVENGE sipuleucel T 64 CHAMPION PCI 64 Zenvia TM 64 ILUVIEN ® 64 Zybrestat 64 Phase 2b monotherapy 64 QLT# 64 Pivotal Trial 64 Phase III psoriasis 64 Laquinimod 64 Microplasmin 64 CIMZIA TM 64 antibody MAb 64 TMC# [002] 64 ProSavin 64 metastatic castration resistant 64 multicenter clinical 64 Androxal TM 64 CIMZIA TM certolizumab pegol 64 SAR# [004] 64 mapatumumab 64 Omacetaxine 64 opioid induced bowel dysfunction 64 PROMACTA 64 Ostarine 64 prospective multicenter randomized 64 octreotide implant 64 AEGR 64 XmAb# 64 Tezampanel 64 TG MV 64 Zoraxel 64 CLIRS trial 64 PSMA ADC 64 Quinamed 64 EndoTAG TM -1 64 active comparator 64 IIa clinical 64 compound INCB# 64 HuMax CD# 64 Onrigin 64 crizotinib PF # 64 preclinical 64 baminercept 64 cell lymphoma CTCL 64 preclinically 64 AZILECT R 64 DermaVir Patch 63 CRMD# 63 VA# [002] 63 unblinding 63 PRTX 63 midstage clinical trial 63 multicenter phase 63 Ereska 63 CLARITY study 63 nab paclitaxel 63 Carfilzomib 63 MERLIN TIMI 63 PDX pralatrexate 63 AeroLEF TM 63 Panzem R 63 Phase III randomized 63 tesmilifene 63 R#/MEM # 63 midstage studies 63 leading oral taxane 63 QNEXA 63 IND enabling 63 Aplidin 63 Cethrin 63 CB2 selective receptor agonist 63 lumiliximab 63 OHR/AVR# 63 obatoclax 63 Degarelix 63 Vicinium TM 63 Aurexis 63 IIb clinical trial 63 Exherin TM 63 DR Cysteamine 63 Dapagliflozin 63 refractory gout 63 midstage clinical trials 63 incyclinide 63 apremilast 63 ocular formulation 63 relapsed multiple myeloma 63 CTAP# Capsules 63 APPRAISE 63 Fibrillex TM 63 CCR5 antagonist 63 Darusentan 63 administered subcutaneously 63 randomized placebo controlled 63 Lu AA# 63 TELCYTA 63 Novolimus 63 Cimzia ® certolizumab pegol 63 Marqibo 63 radiation sensitizer 63 Phase III ALLEGRO 63 huN# DM1 63 Pivotal Study 63 HuMax EGFr 63 ascending dose 63 severe hypercholesterolemia 63 REG2 63 oral FTY# 63 ALN TTR# 63 Phase III Pivotal 63 pharmacodynamic effects 63 multicentre randomized 63 Ophena TM 63 phase IIb III 63 Ambrisentan 63 fostamatinib 63 ISIS # 63 HuMax CD4 63 Phase IIb Clinical Trial 63 dexpramipexole 63 Parkinson disease levodopa induced 63 SYMMETRY trial 63 RhuDex 63 pomalidomide 63 ZYBRESTAT fosbretabulin 63 Pivotal Phase 63 oral deforolimus 63 placebo controlled randomized 63 NVA# 63 Phase III confirmatory 63 LymphoStat B belimumab 63 mGluR5 negative 63 reslizumab 63 olaparib 63 Phase III Trial 63 fidaxomicin Phase 3 63 Tarceva TM 63 seliciclib CYC# 63 Apoptone 63 TRO# 63 Urocidin 63 TG# [003] 63 tolerability 63 HspE7 63 CDP# 63 talactoferrin 63 davunetide intranasal AL 63 Allovectin 7 63 efficacy endpoint 63 Troxatyl 63 Cimzia TM 63 cangrelor 63 sitaxsentan 63 Firazyr 63 ataluren 63 Cethrin R 63 IMGN# 63 orally administered inhibitor 63 LymphoStat B TM 63 Spiegelmer ® 63 randomized Phase 2b 63 MBP# [001] 63 AZX# 63 diarrhea predominant irritable 63 PRIMO CABG 63 investigational drug 63 ACOMPLIA R 63 RDEA# 63 mg/m2 cohort 63 MGCD# [001] 63 CIMZIA ™ 63 CYT# 63 non alcoholic steatohepatitis 63 dose escalation 63 TASKi2 63 evaluating tivozanib 63 Phase 2b kidney transplant 63 eculizumab 63 IRX 2 63 generation purine nucleoside 63 omega interferon 63 Itopride 63 OPT CHF 63 MORAb 63 Synavive 63 albinterferon alfa 2b 62 VEGF inhibitor 62 tramiprosate Alzhemed TM 62 Trofex 62 Bezielle 62 torezolid phosphate 62 liposomal formulation 62 SRT# [003] 62 prucalopride 62 Marketing Authorisation Application 62 initiate Phase 1b 62 otelixizumab 62 iniparib 62 sNDA submission 62 Pimavanserin 62 NOX E# 62 YONDELIS 62 romidepsin 62 Ixempra 62 oxymorphone ER 62 Alocrest 62 Investigational Device Exemption IDE 62 LibiGel Phase III 62 AVADO 62 anticancer compound 62 ENDEAVOR III 62 PRECISE trial 62 ZYBRESTAT 62 intranasal formulation 62 cediranib 62 Omnitarg 62 EchoCRT 62 nitazoxanide 62 Cloretazine 62 nalbuphine ER 62 depsipeptide 62 PROSTVAC ® 62 prospective multicenter 62 masked placebo controlled 62 GOUT 62 trial evaluating PRX# 62 GLYX 62 ospemifene 62 ICA # 62 Phase 1b dose escalation 62 RSD# 62 Maximum Tolerated Dose 62 Pharmacokinetics PK 62 arzoxifene 62 velafermin 62 Phase 2b randomized 62 novel VDA molecule 62 pseudobulbar affect PBA 62 rilonacept 62 Randomized Phase 62 label dose escalation 62 refractory CLL 62 ascending doses 62 eosinophilic asthma 62 Enzastaurin 62 IMC #B 62 Aflibercept 62 Asentar 62 zanolimumab 62 Civacir 62 Anturol TM 62 Evoltra TM 62 Cloretazine R VNP#M 62 ILLUMINATE 62 CRD5 62 Ceflatonin 62 Dyloject TM 62 Dextofisopam 62 dose escalation phase 62 Daclizumab 62 DEB# 62 Tavocept 62 tgAAC# 62 dacetuzumab 62 Zalbin 62 EOquin TM 62 Loramyc R 62 Serdaxin 62 double blind placebo 62 multicenter placebo controlled 62 PEARL SC 62 PEG IFN 62 Vitaxin 62 BrachySil 62 tiapamil 62 AZD# 62 OMNARIS Nasal Spray 62 TASKi3 62 clevidipine 62 RG# [001] 62 Tyrima 62 trastuzumab DM1 62 SinuNase TM 62 Pirfenidone 62 Rezular 62 TPI ASM8 62 blinded placebo controlled 62 RRMS patients 62 thorough QT 62 selective androgen receptor modulator 62 MIRCERA 62 Bicifadine 62 blinatumomab 62 histamine dihydrochloride 62 LY# [002] 62 AIR CF2 62 cariprazine 62 fluticasone furoate 62 PEGylated interferon beta 1a 62 Onalta ™ 62 non nucleoside inhibitor 62 TRX1 62 Vernakalant 62 ozarelix 62 bardoxolone methyl 62 Tanespimycin 62 stated Michelle Berrey 62 trodusquemine 62 zalutumumab 62 pradefovir 62 ofatumumab 62 Glybera R 62 bardoxolone 62 rALLy 62 inhaled formulation 62 Initiate Phase 62 acyclovir Lauriad R 62 mipomersen 62 sunitinib malate 62 SCH # 62 Bronchitol 62 eniluracil 62 dexanabinol 62 CCX# 62 EDEMA3 trial 62 JAK2 inhibitor 62 ThGRF 62 Icatibant 62 investigational 62 ITAX 62 Nexavar sorafenib 62 European Sepsis Trial 62 FTY# fingolimod 62 SPIRIT FIRST 62 randomized multicenter trial 62 GEM OS2 62 sorafenib Nexavar 62 PRT# 62 aclidinium bromide 62 recurrent malignant glioma 62 LE SN# 62 refractory metastatic colorectal cancer 62 inhibitor RG# 62 subcutaneous formulation 62 Iluvien ® 62 safety tolerability 62 OncoVEX GM CSF 62 CBLC# 62 mGluR5 NAM 62 labial herpes 62 adalimumab Humira 62 liprotamase 62 phase III isavuconazole 62 Tesetaxel 62 eprotirome 62 GLPG# 62 lixisenatide 61 Raptiva ® 61 Phase III HEAT 61 CORT # 61 selective modulator 61 pharmacodynamic properties 61 safety tolerability pharmacokinetics 61 investigational monoclonal antibody 61 Blinatumomab 61 cetrorelix 61 investigational antiplatelet agent 61 TKM ApoB 61 PRE SURGE 61 Soliris TM eculizumab 61 visilizumab 61 pharmacodynamics 61 TLK# 61 receptor tyrosine kinase inhibitor 61 MAP# 61 DASISION 61 Meets Primary Endpoint 61 HQK 61 CytoFabTM 61 Golimumab 61 ORENCIA ® 61 interferon gamma 1b 61 LUX Lung 61 GetGoal Phase III 61 ALN TTR 61 recurrent GBM 61 EVIZON 61 tolevamer 61 EDEMA3 61 EMPHASIS HF trial 61 cystinosis patients 61 Dacogen decitabine 61 oral methylnaltrexone 61 Phase 2a Clinical Trial 61 label multicenter 61 LibiGel ® 61 trastuzumab DM1 T DM1 61 Symadex 61 refractory chronic lymphocytic 61 PROSTVAC TM 61 INSPIRE Trial Phase III 61 abiraterone acetate 61 FAME Study 61 EFAPROXYN 61 midstage study 61 neratinib 61 generation PNP inhibitor 61 Silodosin 61 APTIVUS 61 Initiated Phase 61 NUVIGIL 61 desvenlafaxine succinate 61 LUMINATE 61 CALGB 61 SUTENT ® 61 Orazol 61 MEK inhibitor 61 TAXUS Element Stent System 61 aclidinium 61 BRAF inhibitor 61 rindopepimut 61 analgesic efficacy 61 ANG# 61 generation antisense inhibitor 61 bendamustine 61 Diabetic Macular Edema 61 p# inhibitor 61 BrachySil TM 61 IND Investigational New 61 ularitide 61 LymphoStat B 61 Virulizin ® 61 Cetrorelix 61 dose dose escalation 61 MLN# 61 adecatumumab 61 mTOR inhibitor 61 thymalfasin 61 denufosol 61 HGS ETR2 61 Lodotra TM 61 Viramidine 61 NLX P# 61 Prosaptide 61 varespladib 61 atrasentan 61 RezularTM 61 TheraCIM 61 NO# [002] 61 IIa trials 61 orBec 61 RoACTEMRA 61 tafamidis 61 IDX# 61 urocortin 2 61 PS# DARA 61 investigational oral 61 GW# [003] 61 LCP AtorFen 61 injectable formulation 61 ACTEMRA TM 61 ulimorelin 61 RH1 61 LAF# 61 ACV1 61 Panzem R NCD 61 vascular disrupting agent 61 posaconazole 61 valopicitabine 61 preclinical pharmacokinetic 61 pharmacodynamic profile 61 novel histone deacetylase 61 INCB# [003] 61 IPL# 61 rEV# 61 tolerated dose MTD 61 Betaferon ® 61 Iluvien 61 phase III ACCLAIM 61 targeted radiotherapeutic 61 Afatinib 61 Atiprimod 61 AEZS 61 canakinumab 61 ponatinib 61 LIALDA 61 PEG Interferon lambda 61 TKB# 61 PREOS R 61 PF # [002] 61 Perifosine 61 SILENOR TM 61 CCR9 antagonist 61 ZOLINZA 61 ALKS 61 sapacitabine 61 STRIDE PD 61 refractory acute myeloid 61 LY# [003] 61 Marketing Authorization Application 61 Gattex 61 double blinded randomized 61 trabedersen 61 IAP inhibitor 61 metaglidasen 61 symptomatic BPH 61 controlled multicenter 61 Triapine 61 Combination REOLYSIN R 61 Iloperidone 61 pharmacokinetic parameters 61 Atu# 61 daclizumab 61 randomized multicenter Phase III 61 initiated Phase Ib 61 galiximab 61 SinuNase ™ 61 dextromethorphan quinidine 61 ZACTIMA 61 Oglemilast 61 methylnaltrexone 61 Sprycel dasatinib 61 nucleotide analog 61 adipiplon 61 Pivotal Clinical Trial 61 APEX AMI trial 61 BAL# [002] 61 HCV protease inhibitor 61 multicenter randomized controlled 61 CDK inhibitor 61 Virulizin R 61 cetuximab Erbitux 61 vemurafenib 61 NV1FGF 61 TEMSO 61 Omigard 61 Evoltra 61 motesanib 61 oral formulation 61 tipifarnib 61 Marketing Authorization Application MAA 61 Rebif ® 61 relapsing multiple sclerosis 61 ATHX 61 OncoGel 61 Plenaxis TM 61 OMP #M# 61 dirucotide MBP# 61 Q#IR 61 cathepsin K inhibitor 61 PARTNER Trial 61 Sapacitabine 61 humanized anti 61 vosaroxin 61 Biologics License Application BLA 61 glucokinase activator 61 miconazole Lauriad ® 61 afamelanotide 61 TOLAMBA 61 T Pred 61 ARCOXIA 61 Phase 2b Trial 61 QNEXA ® 61 PEGINTRON TM 61 etanercept Enbrel 60 generation URAT1 inhibitor 60 blind randomized placebo 60 Azedra TM 60 AVE# 60 solanezumab 60 Romidepsin 60 PA# [002] 60 AMD# [003] 60 Zerenex 60 PreCISe study 60 PRECiSE 60 ACAPODENE 60 Nuvion 60 NEVO ™ 60 OncoVex 60 entinostat 60 Clolar ® 60 GVAX 60 CD3 monoclonal antibody 60 null responder HCV 60 Locteron ® 60 Amigal 60 Feasibility Trial 60 TRANSFORMS 60 Vicriviroc 60 darusentan 60 oral salmon calcitonin 60 VITAL Trial 60 relapsing remitting multiple sclerosis 60 placebo controlled clinical trials 60 cetuximab Erbitux ® 60 recurrent glioblastoma multiforme 60 microplasmin 60 KNS # 60 ATL/TV# 60 INT# [002] 60 KIACTA ™ 60 Nasulin 60 Aclidinium 60 Amplimexon 60 Kahalalide F 60 ANTEGREN 60 Phase IIa Trial 60 lorcaserin Phase 60 Genz # 60 vilazodone 60 DSMB 60 PHX# 60 heavily pretreated 60 immunomodulatory therapy 60 Dalbavancin 60 Aurora kinase inhibitor 60 allosteric modulator NAM 60 Raptiva R 60 safety tolerability pharmacokinetic 60 Acute Ischemic Stroke 60 MIVI III 60 MAXY alpha 60 Empatic 60 Desmoteplase 60 Torisel 60 EGS# 60 Denufosol 60 intermittent dosing 60 Milnacipran 60 Pazopanib 60 LEP ETU 60 vicriviroc 60 pitavastatin 60 rFIXFc 60 Locteron 60 ACCLAIM II 60 tolerability profile 60 multicenter 60 pan HDAC inhibitor 60 refractory cutaneous T 60 compound AEZS 60 SinuNase 60 treatment naive genotype 60 subanalysis 60 APOPTONE 60 Vilazodone 60 catheter occlusion 60 schizophrenia CIAS 60 ORENCIA R 60 angiogenesis inhibitor 60 hypoxia activated prodrug 60 aurora kinase 60 plasma kallikrein inhibitor 60 resminostat 60 Enobia 60 Hyphanox 60 BOLDER II 60 balsalazide tablet 60 CD# CEA 60 ALTU 60 metastatic castrate resistant 60 tremelimumab 60 dalbavancin 60 MabCampath 60 ROCKET AF 60 multi kinase inhibitor 60 ORMD 60 castration resistant prostate cancer 60 trastuzumab emtansine T DM1 60 multicenter randomized double 60 FDA Approvable Letter 60 Nanobody 60 pediatric glioma 60 BioNumerik 60 castrate resistant prostate cancer 60 controlled multicenter Phase 60 antiplatelet agent 60 pharmacokinetic profile 60 Lupuzor 60 HCD# [002] 60 PRECISE 60 GRN# 60 docetaxel Taxotere R 60 Valdoxan 60 MOZOBIL 60 SILENOR 60 Phase IIa proof 60 Velcade bortezomib 60 ANAVEX #-# [003] 60 SNT-MC#/idebenone 60 TAXUS IV 60 decitabine 60 dextofisopam 60 OMNARIS HFA 60 Ceflatonin R 60 Clonicel 60 VitiGam 60 DAPT 60 label multicenter Phase 60 metastatic malignant 60 multicenter prospective 60 MEK inhibitor RDEA# 60 pharmacodynamic 60 REMUNE R 60 NDA resubmission 60 CG# [003] 60 edifoligide 60 interferon beta 1b 60 Cimzia ® 60 Febuxostat 60 cutaneous T cell 60 edoxaban 60 KB# [002] 60 Prostate AdenoCarcinoma Treatment 60 ENDEAVOR II 60 Ophena 60 laquinimod